The preoperative pan-immune-inflammation value is a novel prognostic predictor for with stage I–III colorectal cancer patients undergoing surgery

Sato, Shun; Shioiri, Takayuki; Ishizuka, Mitsuru; Suda, Kotaro; Shibuya, Norisuke; Hachiya, Hiroyuki; Iso, Yukihiro; Takagi, Kazutoshi; Aoki, Taku; Kubota, Keiichi

doi:10.1007/s00595-021-02448-6

Cited by 21 publications

(31 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fifteen studies encompassing 4942 patients were included in the meta-analyses [ 32 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 ]. The available studies were conducted on several tumors, including CRC, melanoma, breast cancer, and non-small cell lung cancer ( Table 1 ).…”

Section: Resultsmentioning

confidence: 99%

“…One study evaluated both patients treated with immunotherapy (nivolumab and pembrolizumab alone) and targeted therapy with BRAF inhibitors/MEK inhibitors, and separate data for these treatment types were included in the subgroup analyses [ 32 ]. Ten studies included Caucasian patients [ 32 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 48 ], while five studies were conducted in the Far East [ 44 , 45 , 46 , 47 , 49 ]. Most studies had a low risk of bias according to the NOS ( Table 2 ).…”

Section: Resultsmentioning

confidence: 99%

“…Fourteen studies with available DFS/PFS data were included in the analyses [ 32 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 48 , 49 ]. All but two studies reported significantly lower DFS/PFS with higher PIV levels, while the DFS/PFS difference did not reach statistical significance in the studies by Guven et al and Susok et al [ 39 , 42 ].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis

Güven

Şahin

Erul

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: Prognostic scores derived from the blood count have garnered significant interest as an indirect measure of the inflammatory pressure in cancer. The recently developed pan-immune-inflammation value (PIV), an equation including the neutrophil, platelet, monocyte, and lymphocyte levels, has been evaluated in several cohorts, although with variations in the tumor types, disease stages, cut-offs, and treatments. Therefore, we evaluated the association between survival and PIV in cancer, performing a systematic review and meta-analysis. Methods: We conducted a systematic review from the Pubmed, Medline, and Embase databases to filter the published studies until 17 May 2022. The meta-analyses were performed with the generic inverse-variance method with a random-effects model. Results: Fifteen studies encompassing 4942 patients were included. In the pooled analysis of fifteen studies, the patients with higher PIV levels had significantly increased risk of death than those with lower PIV levels (HR: 2.00, 95% CI: 1.51–2.64, p < 0.001) and increased risk of progression or death (HR: 1.80, 95% CI: 1.39–2.32, p < 0.001). Analyses were consistent across several clinical scenarios, including non-metastatic or metastatic disease, different cut-offs (500, 400, and 300), and treatment with targeted therapy or immunotherapy (p < 0.001 for each). Conclusion: The available evidence demonstrates that PIV could be a prognostic biomarker in cancer. However, further research is needed to explore the promise of PIV as a prognostic biomarker in patients with non-metastatic disease or patients treated without immunotherapy or targeted therapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis

Güven

Şahin

Erul

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…What is more, there was a very important point that the methods of obtaining the optimal cutoff value of PIV varied among studies. One study ( 52 ) used the median value of this parameter in the clinical cohort, while others ( 53 – 55 ) used the ROC curve to obtain the optimal value. In this study, we classified the candidate continuous index according to the cutoff point determined by the maximally selected rank statistics using the “maxstat” package of R software ( 56 ), a widely recognized and applied method in many studies ( 57 – 59 ).…”

Section: Discussionmentioning

confidence: 99%

Pan-Immune-Inflammation Value: A New Prognostic Index in Operative Breast Cancer

et al. 2022

View full text Add to dashboard Cite

BackgroundTo build a predictive scoring model based on simple immune and inflammatory parameters to predict postoperative survival in patients with breast cancer.MethodsWe used a brand-new immuno-inflammatory index—pan-immune-inflammation value (PIV)—to retrospectively evaluate the relationship between PIV and overall survival (OS), and based on the results of Cox regression analysis, we established a simple scoring prediction model based on several independent prognostic parameters. The predictive accuracy of the model was evaluated and independently validated.ResultsA total of 1,312 patients were included for analysis. PIV was calculated as follows: neutrophil count (109/L) × platelet count (109/L) × monocyte count (109/L)/lymphocyte count (109/L). According to the best cutoff value of PIV, we divided the patients into two different subgroups, high PIV (PIV > 310.2) and low PIV (PIV ≤ 310.2), associated with significantly different survival outcomes (3-year OS, 80.26% vs. 86.29%, respectively; 5-year OS, 62.5% vs. 71.55%, respectively). Six independent prognostic factors were identified and used to build the scoring system, which performed well with a concordance index (C-index) of 0.759 (95% CI: 0.715–0.802); the calibration plot showed good calibration.ConclusionsWe have established and verified a simple scoring system for predicting prognosis, which can predict the survival of patients with operable breast cancer. This system can help clinicians implement targeted and individualized treatment strategies.

show abstract

“…Previous research has found strong links between pretreatment levels of PIV and clinical outcomes in cancers such as colorectal, breast, esophageal, and small-cell lung cancers, Merkel cell carcinomas, and malignant melanomas. [27][28][29][30][31][32][33][34][35][36][37][38] Furthermore, a PIV variant, the PILE [combination of PIV, lactate dehydrogenase, and Eastern Cooperative Oncology Group (ECOG) performance status] score, as well as a recent meta-analysis by Guven et al, confirmed PIV's prognostic utility in various cancer types and disease stages. 39,40 The prognostic utility of PIV in unresectable LA-PAC patients has paradoxically never been questioned, even though a substantial amount of trustworthy basic and clinical evidence is readily available for other solid malignancies.…”

Section: Introductionmentioning

confidence: 99%

Low Pre-ChemoradiotherapyPan-Immune-Inflammation Value (PIV) Measures Predict Better Survival Outcomes in Locally Advanced Pancreatic Adenocarcinomas

Topkan¹,

Selek²,

Küçük³

et al. 2022

JIR

View full text Add to dashboard Cite

Objective This study sought to determine whether pretreatment pan-immune-inflammation value (PIV) could be used to predict prognosis in patients with locally advanced pancreatic adenocarcinoma (LA-PAC) following definitive concurrent chemoradiotherapy (C-CRT). Methods The outcomes of 178 LA-PAC patients who received definitive C-CRT were analyzed retrospectively. For all patients, the PIV was calculated using the peripheral blood platelet (P), monocyte (M), neutrophil (N), and lymphocyte (L) counts obtained on the first day of C-CRT: PIV=P×M×N÷L. The optimum cutoff values for PIV connected to progression-free (PFS) and overall survival (OS) results were sought using receiver operating characteristic (ROC) curve analysis. The OS and PFS differences between the PIV groups constituted the primary and secondary endpoints, respectively. Results ROC curve analysis indicated that the ideal PIV cutoff was 464 (AUC: 75.9%, sensitivity: 74.1%, specificity: 71.9%), which categorized patients into two groups based on PFS and OS results: low PIV (L-PIV; N = 69) and high PIV (H-PIV; N = 109). According to comparative survival analyses, patients in the L-PIV group had significantly longer median PFS (14.3 vs 7.3 months; HR: 3.04; P<0.001) and OS (25.9 vs 13.3 months; HR: 2.86; P<0.001) than those in the H-PIV group. Although none of the H-PIV patients could survive beyond 5 years, the estimated 5-year OS rate was 29.7% in the L-PIV cohort. In multivariate analyses, besides the L-PIV, N 0 nodal stage, and CA 19–9 ≤ 90 U/mL appeared to be the independent predictors of better PFS (P < 0.05 for each) and OS (P < 0.05 for each) results. Conclusion The present results indicated that pre-C-CRT L-PIV measures were associated with favorable median and long-term PFS and OS results in LA-PAC patients, suggesting that the PIV is a potent and independent novel prognostic biomarker.

show abstract

The preoperative pan-immune-inflammation value is a novel prognostic predictor for with stage I–III colorectal cancer patients undergoing surgery

Cited by 21 publications

References 27 publications

The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis

The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis

Pan-Immune-Inflammation Value: A New Prognostic Index in Operative Breast Cancer

Low Pre-ChemoradiotherapyPan-Immune-Inflammation Value (PIV) Measures Predict Better Survival Outcomes in Locally Advanced Pancreatic Adenocarcinomas

Contact Info

Product

Resources

About